Abstract:Thalassemia is one of the most common monogenic diseases in southern China1. Carriers of thalassemia are usually asymptomatic. However, they have a 25% chance of having symptomatic children if their spouses are also carriers of the same type of thalassemia. Fetuses with homozygous α0-thalassemia usually die in utero during the third trimester or in the early neonatal period, although there are some case reports of long-term survival after intrauterine transfusion therapy2. On the other hand, children with β-thalassemia major usually require life-long blood transfusion for normal growth and development. A prospective prenatal diagnosis program has been carried out to prevent thalassemia at our hospital since 19933. During this period, we encountered two cases in which the pregnant women were referred to prenatal diagnosis for β-thalassemia; however, the fetuses were found to be suffering from homozygous α-thalassemia. Family 1 was referred to our center for prenatal diagnosis in the mother's first trimester of gestation. This was her second pregnancy. Their first son had suffered from severe homozygous β-thalassemia and had been regularly transfused. The child had died at 2 years of age. Both parents had classical β-thalassemia trait based on hematological testing (Table 1). Molecular analysis revealed that the father had a heterozygous β-thalassemia IVS-II-654 (C → T) mutation and the mother a heterozygous β-thalassemia codons 41/42 (–TCTT) mutation. Chorionic villus sampling was then performed at 12 weeks of gestation, and genotyping of the sampled villi showed that the fetus had inherited only the maternal codons 41/42 (–TCTT) mutation. This finding suggested that the phenotype of the fetus was a carrier. The mother continued her pregnancy. However, an additional ultrasound examination at 15 weeks because of vaginal spotting identified fetal cardiomegaly (≥ 0.5 at 12–17 weeks) and placentomegaly (> 18 mm at 12–15 weeks)4. The cardiothoracic ratio was 0.53 and placental depth was 3.2 cm. These signs led us to exclude Hb Bart's hydrops fetalis in an area with high prevalence of thalassemia. The frozen DNA samples of the family were retrieved, and α-globin genotyping revealed that both parents had heterozygous α0-thalassemia (--SEA(SoutheastAsian)) and the fetus had homozygous α0-thalassemia (--SEA/--SEA). The pregnancy was terminated at 16 weeks of gestation at the parents' request. Family 2 was referred to our center for prenatal diagnosis at 18 weeks of gestation. This was the mother's first pregnancy. Both parents were found to be positive for β-thalassemia by hematological testing (Table 1). Molecular analysis revealed that both parents had a heterozygous β-thalassemia IVS-II-654 (C → T) mutation. An anatomical scan before invasive testing identified fetal cardiomegaly (≥ 0.52 at 18–20 weeks), with a cardiothoracic ratio of 0.56 and a placental depth of 3.5 cm. The decision was made to sample the fetal blood. Hb Bart's hydrops fetalis syndrome was confirmed, with the following hematological findings: Hb Bart's 76.6%, Hb (A + Portland) 23.4%, HbF 0% and HbA2 0%. Genotyping of α-globin showed that both parents had co-existent α0-thalassemia (--SEA) and the fetus had homozygous α0 thalassemia (--SEA/--SEA). The pregnancy was terminated at 19 weeks of gestation. The carrier rates of α0-thalassemia (--SEA) and β-thalassemia are 4.1% and 2.5%, respectively, in southern China1. This means that the chance of finding an individual with co-inheritance of α0- and β-thalassemia in the population is theoretically 1/1000. In other words, one in every 25 β-thalassemia carriers co-inherits α0-thalassemia. It is well known that routine screening testing, such as mean cell volume (MCV) and HbA2 level, cannot distinguish double heterozygotes of α- and β-thalassemia from the pure heterozygous β-thalassemia state5-7. DNA diagnosis is necessary for differentiation. Diagnosis of this double heterozygotic state is important for genetic counseling, since, unlike the typical β-thalassemia carriers, these individuals will be at risk of having offspring with homozygous α0-thalassemia if their partners are also α0-thalassemia heterozygotes. Hence, in our prenatal thalassemia screening program, we determine by molecular analysis the α0-thalassemia status in β-thalassemia partners in couples presumed to be discordant for α- and β-thalassemia on hematological findings8. However, when both members of a couple are found on screening to be β-thalassemia carriers, it may not be cost-effective to perform α-globin genotyping on both partners. In this situation, the chance of delivering a homozygous α0-thalassemia offspring is remote (theoretically 1/2500). However, one should be aware of the risk of their pregnancies being affected by homozygous α0-thalassaemia. Since invasive prenatal testing is always necessary for these β-thalassemia at-risk pregnancies, simultaneously determining the α-globin genotype of the fetus is a method of choice. Another option is to perform serial ultrasound examinations to exclude an affected pregnancy from 12 weeks of gestation4. C. Liao*, X.-M. Xie*, D.-Z. Li*, * Prenatal Diagnostic Center, Guangzhou Maternal and Neonatal Hospital, Guangzhou Medical College, Guangzhou, Guangdong 510180, People's Republic of China

Preimplantation Genetic Diagnosis of Human Embryos with Α-Thalassemia

Medium-based Noninvasive Preimplantation Genetic Diagnosis for Human Α-Thalassemias-sea.

Prevention of Hb Bart’s (γ4) Disease Associated with the – –Thaiα0-Thalassemia Deletion in Mainland China

Successful Preimplantation Genetic Diagnosis of Α-and Β-Double Thalassemia Combined with HLA Typing by Next Generation Sequencing

Using affected embryos to establish linkage phase in preimplantation genetic testing for thalassemia

A Comprehensive Preimplantation Genetic Testing Approach for SEA-type Α-Thalassemia by Fluorescent Gap-Polymerase Chain Reaction Combined with Haplotype Analysis

Embryo genome profiling by single-cell sequencing for preimplantation genetic diagnosis in a β-thalassemia family

Application of short tandem repeats (STRs) in the preimplantation genetic diagnosis (PGD) of α-thalassemia

Technically feasible solutions to challenges in preimplantation genetic testing for thalassemia: experiences of multiple centers between 2019 and 2022

Application of the High-throughput Technologies in Preimplantation Genetic Diagnosis

Comprehensive Preimplantation Genetic Testing by Massively Parallel Sequencing

A Pilot Study of Noninvasive Prenatal Diagnosis of Alpha- and Beta-Thalassemia with Target Capture Sequencing of Cell-Free Fetal DNA in Maternal Blood

AB034. Hemoglobinopathies in China and SEA: Rapid Targeted Deep Sequencing for Molecular Screening and Clinical Genotyping in Subjects with Hemoglobinopathies

Appropriate whole genome amplification and pathogenic loci detection can improve the accuracy of preimplantation genetic diagnosis for deletional α-thalassemia

Routine antenatal molecular testing for α-thalassemia at a tertiary referral hospital in China: ten years of experience

Integration of targeted sequencing and pseudo-tetraploid genotyping into clinically assisted decision support for β-thalassemia invasive prenatal diagnosis

Prenatal diagnosis of thalassemia in 695 pedigrees from southeastern China: a 10‐year follow‐up study

Prenatal diagnosis of beta-thalassemia by reverse dot-blot hybridization in southern China

Invasive Molecular Prenatal Diagnosis of Alpha and Beta Thalassemia among Hakka Pregnant Women

Two Cases of Homozygous Alpha0-Thalassemia Diagnosed Prenatally in Pregnancies at Risk for Beta-Thalassemia in China.

Noninvasive prenatal testing for β-thalassemia by targeted nanopore sequencing combined with relative haplotype dosage (RHDO): a feasibility study